Results 101 to 110 of about 181,344 (173)

Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer. [PDF]

CPT Pharmacometrics Syst Pharmacol
Franzese RC, Qin L, Fu S, Rich B, Zografos E, Zierhut ML, Visser SAG.   +6 more
europepmc   +1 more source

Assessment of Programmed Cell Death Ligand-1 Expression in Oral Potentially Malignant Disorders and Tumor-Free Surgical Margins of Oral Squamous Cell Carcinoma: Protocol for a Retrospective Cross-Sectional Study. [PDF]

JMIR Res Protoc
Sonone A, Hande A, Patil S, Pakhale A, Sharma P.   +4 more
europepmc   +1 more source

Prognostic significance of PD-L1/PD-1 co-expression and CXCR3-driven inflammatory signatures in Egyptian patients with lymphoproliferative neoplasms. [PDF]

World J Clin Oncol
Sherief DE, Nosair N, Abdelhameed AM, Sadaka E, Othman AAA, Elgamal R.   +5 more
europepmc   +1 more source

Clinical Characteristics and Risk Factors of Immune Checkpoint Inhibitor-Related Myocarditis: A Real World Observational Study. [PDF]

Clin Cardiol
Zhan M, Long Q, Liu R, Huang L, Wu B, Xu T, He J.   +6 more
europepmc   +1 more source

Thyroid and cortisol endocrinopathies and survival in cancer patients treated with immune checkpoint inhibitors in UAE. [PDF]

J Endocr Soc
Alqedra M, Fahmayee B, Wahba L, Ansari J, Govender RD, Al-Shamsi S, Almazrouei R.   +6 more
europepmc   +1 more source

Independent Testing of Published CT Models for PD-L1 Status in Non-Small Cell Lung Cancer. [PDF]

Radiology
O'Shea R, Horst C, Manickavasagar T, Josephides E, Hunter S, Taniere P, Nonaka D, Van Hemelrijck M, Spicer J, Hughes DJ, Cook GJR, Bille A, Karapanagiotou E, Goh V.   +13 more
europepmc   +1 more source

Lack of cytoplasmic expression of a new marker programmed cell death ligand-1 in tumor cells is significant. [PDF]

World J Exp Med
Senchukova MA, Zubareva EY, Saidler NV, Krivolapova LV.   +3 more
europepmc   +1 more source

Severe Immune-related Adverse Events and Their Effect on Survival in Patients With Advanced Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors. [PDF]

Cancer Diagn Progn
Nojiri T, Omura A, Nishimura H, Iede K, Takeyasu Y, Katsushima U, Higashiyama M.   +6 more
europepmc   +1 more source

A Case of Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus Achieving Pathologic Complete Response Following Combination Therapy With Lenvatinib and Pembrolizumab. [PDF]

IJU Case Rep
Takayama H, Sano T, Hirao K, Motoki Y, Taniguchi H, Yanishi M, Uchida K, Kinoshita H.   +7 more
europepmc   +1 more source

Navigating the Labyrinth of Hepatocellular Carcinoma: Leveraging AI/ML for Precision Oncology. [PDF]

Oncol Res
Manan A, Ilyas S.
europepmc   +1 more source